BSX

Summary

Underweight BSX (Boston Scientific) — reduce exposure at current levels. The stock is overbought (RSI 71.6, near upper Bollinger ~$52.87) within a long-term downtrend (~27% below the 200-day SMA at $70.92), and the structural overhang in WATCHMAN/EP argues for trimming rather than adding. Action plan: (1) do not initiate longs at ~$52.28–52.33; (2) do not initiate shorts given insider buying and short-term momentum; (3) a pullback toward the $49–50 zone (10-day EMA $49.59) would be the only place to reconsider a long entry; (4) treat a break below the 50-day SMA at $46.13 as invalidation of the medium-term uptrend and step aside; (5) only turn constructive on a confirmed breakout above $52.87 on strong volume AND fundamental stabilization in WATCHMAN/EP. Position sizing: reduce now; if a long is later triggered on a pullback, size modestly (half or less) and set a stop ~1.5–2× ATR (~$2.45–3.26) below entry. Time horizon: tactical 5–10 day window, with structural thesis unresolved until 2028.

The case

The evidence is genuinely balanced, but the operative posture is to reduce exposure rather than hold at current levels.

Bull case: CEO insider buying of ~$10M (a 13% increase in personal stake) at multi-year lows is a meaningful contrarian signal; PEG 0.73 and forward P/E 15.2 look cheap for a high-margin med-tech; ~75% of revenue still growing at long-run rates (the market prices BSX as if WATCHMAN were the whole company); short/medium-term technicals are bullish (price above 10 EMA and 50 SMA, MACD positive and expanding, VWMA confirmation). The 21% counter-trend rally off July lows shows real momentum.

Bear case: the guidance cut is structural, not cyclical — WATCHMAN and EP were the growth engines justifying the premium, and recovery is pushed to 2028; product recalls in growth categories are more damaging than routine; put/call volume ratio 2.74 with IV at 52% signals elevated downside tail risk; the PEG denominator is shrinking (forward earnings already cut); price is ~27% below the 200-day SMA with RSI overbought near the upper Bollinger band — a classic mean-reversion setup against chasing.

Reconciliation: The insider-buying point is strong but not decisive ($10M is meaningful to the CEO but immaterial vs. a $75.8B market cap). The structural-headwind point is strong but not decisive (75% of revenue still growing). The valuation argument cuts both ways — cheap on PEG, but the denominator is shrinking. The options-flow bearishness is real but plausibly hedging after a 54% decline rather than a directional short.

Past-decision reflection: My prior BSX Buy (2026-07-24, +3.6% alpha) was a volatility-compression setup that resolved upward — a different regime from today's overbought counter-trend rally. The recurring lesson (half-sizing left ~1.8% foregone alpha) is not applicable here because I am reducing exposure rather than establishing a directional position; there is no compelling setup to size.

Conclusion: With the stock overbought within a downtrend and structural overhang unresolved, the correct posture is to reduce exposure. A pullback to support would be the only place to reconsider a long entry, and a breakdown below $46.13 would confirm the bearish case. Committing to a full exit would be overfitting noise in a genuinely mixed setup, but trimming to Underweight is the appropriate risk posture.

What would weaken it

• Structural guidance cut in WATCHMAN/EP with recovery pushed to 2028
• Overbought RSI near upper Bollinger within a long-term downtrend
• Elevated downside tail risk (put/call 2.74, IV 52%)